Cannabinoid Synergy With Hyperbaric Oxygen
Dr. Bogner’s presentation at AutismOne 2018 on Cannabinoid Synergy
The literature supports various pathophysiologies in individuals affected with autism spectrum disorder (ASD), including cerebral hypoperfusion, inflammation, mitochondrial dysfunction and oxidative stress. It has been hypothesized that children affected with ASD might benefit from Hyperbaric oxygen treatment (HBOT) owing to the increase in cerebral perfusion occurring during treatment. Here I present my theories on potential cannabinoid synergy with hyperbarics.
The cell-danger response and endocannabinoid signaling pathways have been described as possible key elements in the pathophysiology of microglia driven neuroinflammation, with resulting behavioral problems associated with ASD.
Cannabinoid Synergy = Phytocannabinoid + Hyperbaric Oxygen Synergy
With the growing body of evidence in the literature that describes beneficial phytocannabinoid effects in patients affected with ASD, we highlight the principle mechanisms of a novel concept, e.g. phytocannabinoid-hyperbaric-oxygen synergy and its role in paving the way for faster and lasting clinical benefits. HBOT is approved for several clinical disorders including decompression sickness, gas gangrene, cyanide poisoning and diabetic wounds. Inhalation of above-atmospheric oxygen might result in an elevation of arterial partial pressure of oxygen, leading to increased oxygen delivery to the brain.
HBOT might also have anti-inflammatory properties due to the reduction of pro-inflammatory cytokines (tumor necrosis factor–α, interferon-γ, and interleukins 1 and 6). Furthermore, HBOT might improve mitochondrial dysfunction, as well as up-regulate the production of antioxidant enzymes. While some studies suggest improved cerebral perfusion, others showed decreased markers of inflammation and did not worsen oxidative stress markers in children with ASD. In the reviewed studies, HBOT had minimal adverse effects and was well tolerated.
Most of the reviewed studies relied on changes in behavioral measurements, which may lag behind physiological changes. In our protocol, we utilize different ATAs in monoplace chambers for all ASD children. The molecular collusion of hyperbaric oxygen and phytocannabinoids suggests synergistic properties, aiding in anti-inflammation, detoxification, improved synaptic plasticity and central nervous system homeostasis.